Related Experiment Video
Updated: May 7, 2026
Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
Published on: June 13, 2014
Targeting receptor tyrosine kinases in HER2-negative breast cancer
Purpose Of Review:
The targeting of receptor tyrosine kinases (RTKs) has been a major area for breast cancer therapy, exemplified by the targeting of HER2-amplified breast cancer.
Recent Findings:
We review the data on the activation of RTKs in HER2-negative breast cancer, and discuss the clinical translational challenge of identifying cancers that are reliant on a specific kinase for growth and survival. Substantial evidence suggests that subsets of breast cancer may be reliant on specific kinases, and that this could be exploited therapeutically. The heterogeneity of breast cancer, however, and the potential for adaptive switching between RTKs after inhibition of a single RTK, present challenges to targeting individual RTKs in the clinic
Summary:
Targeting of RTKs in HER2-negative breast cancer presents a major therapeutic opportunity in breast cancer, although robust selection strategies will be required to identify cancers with activation of specific RTKs if this potential is to be realized.
Insights
Targeting receptor tyrosine kinases (RTKs) in HER2-negative breast cancer offers a promising therapeutic avenue. Identifying specific kinase dependencies is crucial for effective treatment strategies in this heterogeneous disease.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Receptor tyrosine kinases (RTKs) are key targets in breast cancer therapy, notably in HER2-amplified cases.
- Understanding RTK activation in HER2-negative breast cancer is critical for developing new treatments.
Purpose of the Study:
- To review the activation of RTKs in HER2-negative breast cancer.
- To discuss the challenges in identifying specific kinase dependencies for targeted therapy.
Main Methods:
- Literature review of data on RTK activation in breast cancer.
- Analysis of clinical translational challenges in RTK-targeted therapy.
Main Results:
- Evidence suggests subsets of HER2-negative breast cancer rely on specific RTKs for growth.
- Breast cancer heterogeneity and adaptive resistance mechanisms pose challenges for single RTK inhibition.
Conclusions:
- Targeting RTKs in HER2-negative breast cancer represents a significant therapeutic opportunity.
- Robust patient selection strategies are essential to identify cancers with specific RTK activation for successful treatment.
More Related Videos
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:57Targeted Cancer Therapies
02:38Mitogens and the Cell Cycle
01:27Transducer Mechanism: Enzyme-Linked Receptors
Major types that are helpful drug targets include:
01:26Receptor Tyrosine Kinases
01:00Enzyme-linked Receptors
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...